TABLE 2.
Absolute viral load analysis by RT-PCR and DDPCR during the treatment days.
| Variables | N | Total1 | Azvudine (N = 1431) | Placebo (N = 1381) | P-value2 |
| Viral load (D0) | 281 | 9.971 ± 4.257 (11.553) | 10.239 ± 3.985 (11.593) | 9.694 ± 4.519 (11.394) | 0.543 |
| Viral load (D1) | 275 | 8.631 ± 4.897 (10.756) | 8.359 ± 5.083 (10.834) | 8.909 ± 4.702 (10.717) | 0.634 |
| Viral load (D3) | 275 | 5.733 ± 5.503 (1.037) | 4.452 ± 5.564 (969) | 7.023 ± 5.146 (10.000) | <0.001 |
| Viral load (D5) | 242 | 4.285 ± 5.189 (971) | 3.016 ± 4.897 (0) | 5.513 ± 5.187 (9.642) | <0.001 |
| Viral load (D7) | 186 | 1.773 ± 3.613 (63) | 1.483 ± 3.516 (0) | 1.987 ± 3.684 (967) | <0.001 |
| Viral load (D9) | 119 | 1.276 ± 3.282 (0) | 1.439 ± 3.653 (0) | 1.214 ± 3.149 (29) | 0.064 |
| Viral load (D11) | 70 | 556 ± 2.230 (0) | 902 ± 2.637 (0) | 462 ± 2.124 (0) | 0.712 |
| Viral load (D13) | 41 | 334 ± 1.526 (0) | 501 ± 536 (491) | 294 ± 1.685 (0) | 0.002 |
| DDPCR (D1) | 279 | 36.473 ± 69.608 (7.004) | 31.452 ± 64.185 (5,672) | 41.751 ± 74,764 (11.619) | 0.220 |
| DDPCR (D3) | 268 | 25.715 ± 57,361 (3,114) | 13,063 ± 36,706 (638) | 38.749 ± 70.572 (11.466) | <0.001 |
| DDPCR (D5) | 219 | 23.461 ± 56,423 (1,141) | 3,828 ± 15,666 (0) | 38,783 ± 70,409 (9,441) | <0.001 |
| DDPCR (D7) | 165 | 12,468 ± 34,138 (107) | 1,454 ± 5,569 (0) | 18,761 ± 41,355 (2,456) | <0.001 |
| DDPCR (D9) | 110 | 11,831 ± 39,217 (77) | 10,298 ± 52,889 (0) | 12,433 ± 32,742 (880) | <0.001 |
| DDPCR (D11) | 60 | 3,645 ± 11,721 (26) | 379 ± 686 (0) | 4,378 ± 12,875 (72) | 0.153 |
| DDPCR (D13) | 36 | 329 ± 1,525 (0) | 394 ± 735 (0) | 313 ± 1,670 (0) | 0.049 |
1Mean ± standard deviation (Median).
2Mann–Whitney test; Wilcoxon rank sum exact test.